Piper Sandler has initiated GeneDx (NASDAQ:WGS) at overweight saying that the genetic testing company is addressing a rare disease testing market that has room to grow.
The firm set a $110 price target (~29% upside based on July 8 close).
Analyst David Westenberg said the company has "first-mover advantage with 20+ years of meticulously curated patient data and the largest dedicated salesforce in the industry."
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.